Get the Stockscreener App
40.83
1.57%
-0.65
Gsk Plc Adr stock is traded at $40.83, with a volume of 4.74M.
It is down -1.57% in the last 24 hours and up +6.83% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$41.48
Open:
$41.24
24h Volume:
4.74M
Relative Volume:
1.01
Market Cap:
$83.11B
Revenue:
$40.95B
Net Income/Loss:
$5.16B
P/E Ratio:
18.81
EPS:
2.1708
Net Cash Flow:
$5.47B
1W Performance:
+0.81%
1M Performance:
+6.83%
6M Performance:
+5.02%
1Y Performance:
-5.29%
1-Day Range:
$40.50
$41.39
1-Week Range:
$39.37
$41.53
52-Week Range:
$31.71
$43.62
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
40.83 | 81.54B | 40.95B | 5.16B | 5.47B | 2.1708 |
|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Downgrade | Berenberg | Buy → Hold |
| Apr-15-25 | Initiated | Exane BNP Paribas | Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
Ancora Advisors LLC Has $123,000 Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
Everstar Asset Management LLC Increases Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Acadian Asset Management LLC Purchases 2,663,270 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Chelsea Counsel Co. Sells 20,000 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Fred Alger Management LLC Has $2.02 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
NewEdge Advisors LLC Has $3.51 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Rep. Robert B. Aderholt Sells GSK PLC Sponsored ADR (NYSE:GSK) Stock - Defense World
Aprio Wealth Management LLC Makes New $248,000 Investment in GSK PLC Sponsored ADR $GSK - MarketBeat
Baird Financial Group Inc. Buys 1,179 Shares of GSK PLC Sponsored ADR $GSK - Defense World
National Wealth Management Group LLC Buys New Shares in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Position Increased by Clark Capital Management Group Inc. - MarketBeat
Vident Advisory LLC Purchases 8,294 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
With Asthma-Related ER Visits Increasing, AAFA Names 2025 Asthma Capitals - GlobeNewswire Inc.
Alyeska Investment Group L.P. Purchases New Shares in GSK PLC Sponsored ADR $GSK - MarketBeat
Royal Bank of Canada Has $293.69 Million Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Kestra Advisory Services LLC Cuts Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
OMERS ADMINISTRATION Corp Buys Shares of 76,100 GSK PLC Sponsored ADR $GSK - MarketBeat
Northwestern Mutual Wealth Management Co. Grows Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Causeway Capital Management LLC Grows Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
ICONIQ Capital LLC Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Deutsche Bank AG Acquires 1,820 Shares of GSK PLC Sponsored ADR $GSK - Defense World
British Equities Extend Losses; GSK Bags Approval for Antibiotic - 富途牛牛
The Best Healthcare Stocks to Buy - Morningstar
GSK Plc ADR Inc. (GSK) Price Performance: The Impact of Insider Trading and Institutional Holdings - investchronicle.com
Rep. Lisa C. McClain Buys GSK PLC Sponsored ADR (NYSE:GSK) Shares - MarketBeat
The 10 Best Companies to Invest in Now - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plcGSK - cnhinews.com
GSK PLC Sponsored ADR (NYSE:GSK) Shares Bought by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
GSK Plc ADR (GSK Stock: A Sea of Opportunity - investchronicle.com
Pomerantz LLP Investigates GSK Securities Fraud Claims - AInvest
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar
Company News for Jul 31, 2025 - The Globe and Mail
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise - TradingView
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology - Ariva
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
GSK Plc ADR (GSK) Stock: A Year of Stock Market Dynamics - investchronicle.com
Fifth Third Bancorp Inc. (FITB) Price Performance Over the Years: A Comparative Study - investchronicle.com
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):